Starling Oncology, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Starling Oncology, Inc. (DFPH) reported Business Acquisition, Pro Forma Net Income (Loss) of -$83.18 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-03-28
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2022-12-31 was -$13.04M.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2022-09-30 was -$2.52M.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2022-06-30 was -$5.16M, a 225.06% decline year-over-year.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was -$8.94M.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for fiscal 2023 was -$83.18M, a 218986.84% decline from fiscal 2022.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for fiscal 2022 was $38.00K.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for fiscal 2021 was -$6.03M.
- Starling Oncology, Inc. business acquisition, pro forma net income (loss) for fiscal 2020 was -$12.20M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | -$83.18M 10-K · filed 2024-03-28 | ||||
| 2022-12-31 | -$13.04M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$15.56M derived: sum of 2 quarters · filed 2024-03-28 | -$20.72M derived: sum of 3 quarters · filed 2024-03-28 | $38.00K 10-K · filed 2024-03-28 | $2.14M 10-K · filed 2023-03-16 |
| 2022-09-30 | -$2.52M 10-Q · filed 2022-11-09 | -$7.68M derived: sum of 2 quarters · filed 2022-11-09 | $13.08M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | -$5.16M 10-Q · filed 2022-08-09 | $15.03M 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | -$8.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$10.71M derived: sum of 2 quarters · filed 2023-03-16 | -$6.59M derived: sum of 3 quarters · filed 2023-03-16 | -$6.03M 10-K · filed 2023-03-16 | -$1.45M 10-K · filed 2022-03-11 |
| 2021-09-30 | -$1.78M 10-Q · filed 2022-11-09 | $2.35M derived: sum of 2 quarters · filed 2022-11-09 | $2.90M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $4.13M 10-Q · filed 2022-08-09 | $4.05M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | -$12.20M 10-K · filed 2022-03-11 |